Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/0333102416649092 http://scihub22266oqcxt.onion/10.1177/0333102416649092 C5405839!5405839!27165493     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cephalalgia 2017 ; 37 (5): 423-34 Nephropedia Template TP {{tp|p=27165493|t=2017. Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache |pdf=|usr=}}{{27165493}} gab.com Text Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache JO: Cephalalgia http://www.kidney.de/pget.php?&tw=1&pmid=27165493 #FOAvip Objectives: The sphenopalatine ganglion (SPG) plays a pivotal role in cluster headache (CH) pathophysiology as the major efferent parasympathetic relay. We evaluated the long-term effectiveness of SPG stimulation in medically refractory, chronic CH patients. Methods: Thirty-three patients were enrolled in an open-label follow-up study of the original Pathway CH-1 study, and participated through 24 months post-insertion of a microstimulator. Response to therapy was defined as acute effectiveness in???50% of attacks or a???50% reduction in attack frequency versus baseline. Results: In total, 5956 attacks (180.5?±?344.8, range 2?1581 per patient) were evaluated. At 24 months, 45% (n?=?15) of patients were acute responders. Among acute responders, a total of 4340 attacks had been treated, and in 78% of these, effective therapy was achieved using only SPG stimulation (relief from moderate or greater pain or freedom from mild pain or greater). A frequency response was observed in 33% (n?=?11) of patients with a mean reduction of attack frequency of 83% versus baseline. In total, 61% (20/33) of all patients were either acute or frequency responders or both. The majority maintained their therapeutic response through the 24-month evaluation. Conclusions: In the population of disabled, medically refractory chronic CH patients treated in this study, SPG stimulation is an effective acute therapy in 45% of patients, offering sustained effectiveness over 24?months of observation. In addition, a maintained, clinically relevant reduction of attack frequency was observed in a third of patients. These long-term data provide support for the use of SPG stimulation for disabled patients and should be considered after medical treatments fail, are not tolerated or are inconvenient for the patients. Twit Text FOAVip Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache ????Cephalalgia http://www.kidney.de/pget.php?&tw=1&pmid=27165493 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27165493 #FOAvip English Wikipedia <ref>{{Cite pmid|27165493}}</ref> Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache #MMPMID27165493 Jürgens TP; Barloese M; May A; Láinez JM; Schoenen J; Gaul C; Goodman AM; Caparso A; Jensen RH Cephalalgia 2017[Apr]; 37 (5): 423-34 PMID27165493show ga Objectives: The sphenopalatine ganglion (SPG) plays a pivotal role in cluster headache (CH) pathophysiology as the major efferent parasympathetic relay. We evaluated the long-term effectiveness of SPG stimulation in medically refractory, chronic CH patients. Methods: Thirty-three patients were enrolled in an open-label follow-up study of the original Pathway CH-1 study, and participated through 24 months post-insertion of a microstimulator. Response to therapy was defined as acute effectiveness in???50% of attacks or a???50% reduction in attack frequency versus baseline. Results: In total, 5956 attacks (180.5?±?344.8, range 2?1581 per patient) were evaluated. At 24 months, 45% (n?=?15) of patients were acute responders. Among acute responders, a total of 4340 attacks had been treated, and in 78% of these, effective therapy was achieved using only SPG stimulation (relief from moderate or greater pain or freedom from mild pain or greater). A frequency response was observed in 33% (n?=?11) of patients with a mean reduction of attack frequency of 83% versus baseline. In total, 61% (20/33) of all patients were either acute or frequency responders or both. The majority maintained their therapeutic response through the 24-month evaluation. Conclusions: In the population of disabled, medically refractory chronic CH patients treated in this study, SPG stimulation is an effective acute therapy in 45% of patients, offering sustained effectiveness over 24?months of observation. In addition, a maintained, clinically relevant reduction of attack frequency was observed in a third of patients. These long-term data provide support for the use of SPG stimulation for disabled patients and should be considered after medical treatments fail, are not tolerated or are inconvenient for the patients. äLong-term effectiveness of sphenopalatine ganglion stimulation for clu(epmc).pdf DeepDyve Pubget Overpricing